148 Ces Urol 2023; 27(3): 139-150 PŘEHLEDOVÉ ČLÁNKY 6. Chang YH, Chuang CK, Pang ST, et al. Prognostic value of TNM stage and tumor necrosis for renal cell carcinoma. Kaohsiung Journal of Medical Sciences. 2011; 27(2): 59–63. 7. An JS, Packiam VT, Chennamadhavuni A, et al. Patient Characteristics and Survival Outcomes of Non ‑Metastatic, Non‑Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 2022; 11. 8. Wagener N, Edelmann D, Benner A, et al. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non‑metastatic disease. Plos One. 2017; 12(9). 9. Warren AY, Harrison D. WHO/ISUP classification, grading and pathological staging of renal cell carcinoma: standards and controversies. World Journal of Urology. 2018; 36(12): 191326. 10. Lin TF, Lin WR, Chen M, et al. Compare fuhrman nuclear and chromophobe tumor grade on chro‑ mophobe RCC. Open Medicine. 2019; 14(1): 336–42. 11. Ohashi R, Martignoni G, Hartmann A, et al. Multi‑institutional re‑evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two‑tiered grading scheme. Virchows Archiv. 2020; 476(3): 409–18. 12. de Peralta‑Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma - A study of 101 cases. American Journal of Surgical Pathology. 2001; 25(3): 275–84. 13. Lee SE, Byun SS, Oh JK, et al. Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma. Journal of Urology. 2006; 176(4): 1332–7. 14. Vasudev NS, Wilson M, Stewart GD, et al. Challenges of early renal cancer detection: symptom pa‑ tterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. Bmj Open. 2020; 10(5). 15. O’Brian D, Prunty M, Hill A, Shoag J. The Role of C‑Reactive Protein in Kidney, Bladder, and Prostate Cancers. Frontiers in Immunology. 2021; 12. 16. Teishima J, Kobatake K, Shinmei S, et al. The effect of kinetics of C‑reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor. Urologic Oncology‑Seminars and Original Investigations. 2017; 35(11). 17. Jabs WJ, Busse M, Kruger S, et al. Expression of C‑reactive protein by renal cell carcinomas and una‑ ffected surrounding renal tissue. Kidney International. 2005; 68(5): 2103–10. 18. Tamura K, Matsushita Y, Watanabe H, et al. Feasibility of the ACL (albumin, C‑reactive protein and lactate dehydrogenase) model as a novel prognostic tool in patients with metastatic renal cell carcinoma previously receiving first‑line targeted therapy. Urologic Oncology‑Seminars and Original Investigations. 2020; 38(1). 19. Tamura K, Ando R, Takahara K, et al. Development of novel ACN (albumin, C‑reactive protein and neutrophil‑to‑lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first‑line molecular‑targeted therapy. Urologic Oncology‑Seminars and Original Investigations. 2021; 39(1). 20. Yilmaz H, Yilmaz A, Demirag G. Prognostic significance of hemoglobin‑to‑red cell distribution width ratio in patients with metastatic renal cancer. Future Oncology. 2021; 17(29): 3853–64. 21. Basmaci I, Celik S, Sefik E, et al. Evaluation of the Prognostic Value of Preoperative Neutrophil ‑tolymphocyte Ratio in Renal Cell Carcinoma. Journal of Urological Surgery. 2019; 6(3): 218– 24. 22. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006; 107(8): 1793–800. 23. Zhang ND, Zhang HN, Zhu DQ, et al. Prognostic role of pretreatment lactate dehydrogenase in pa‑ tients with metastatic renal cell carcinoma: a systematic review and meta‑analysis. International Journal of Surgery. 2020; 79: 66–73. 24. Shen J, Chen Z, Zhuang QF, et al. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta‑Analysis. Plos One. 2016; 11(11).
RkJQdWJsaXNoZXIy NDA4Mjc=